Genital Warts Pipeline Insight Report 2020: Insights into 30 Companies & Pipeline Drugs - ResearchAndMarkets.com

The "Genital Warts - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This Genital Warts - Pipeline Insight, 2020, report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Genital Warts Emerging Drugs Chapters

This segment of the Genital Warts report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Genital Warts Emerging Drugs

VP-102: Verrica Pharmaceuticals

Verricas lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Verrica is developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

SB206: Novan

Novan is developing SB206 as a topical antiviral gel for the treatment of viral skin infections, including external genital warts (EGW) caused by human papillomavirus (HPV). SB206 exhibited a dose responsive pharmacologic effect with complete inhibition of papilloma growth compared to topical imiquimod in an in vivo model. NVN1000, the active pharmaceutical ingredient in SB206, exhibited a dose dependent decrease in HPV viral replication in human raft cell culture model.

CB-06-02: Cassiopea

CB-06-02, a NCE, immune modulator is being developed for the treatment of genital warts. Cassiopea believes it is the first potential treatment for this condition based on tellurium, a rare element. It acts as a low-toxicity immunomodulator in supporting the natural immune response against Human Papilloma Virus, or HPV. Based on the drug profiling Cassiopea has performed to date, the Company believes CB-06-02 has the potential to have a faster onset of action and a lower recurrence rate than currently available treatments.

Genital Warts: Therapeutic Assessment

This segment of the report provides insights about the different Genital Warts drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Genital Warts

There are approx. 30+ key companies which are developing the therapies for Genital Warts. The companies which have their Genital Warts drug candidates in the most advanced stage, i.e. phase II include Verrica Pharmaceuticals and others

Phases

This report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Genital Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenius
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Genital Warts: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II I, preclinical and discovery stage. It also analyses Genital Warts therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Warts drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Genital Warts R&D. The therapies under development are focused on novel approaches to treat/improve Genital Warts.
• In July 2018, Cassiopea announced that the proof of concept phase II clinical trial for its CB-06-02 topical 15% immune modulator tellurium-based gel for the treatment of external genital warts in women demonstrated statistically significant successful complete clearance rates in the PP population and successful complete clearance rates in the ITT population.

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Genital Warts drugs?
• How many Genital Warts drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Warts?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Genital Warts therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Genital Warts and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ViroXis Corporation
• bioRASI, LLC
• Verrica Pharmaceuticals Inc.
• Orgenesis
• Heber Biotec
• Cassiopea
• Novan
• Peritech Pharma
• Novartis

Key Products

• VIR007
• Ranpirnase
• CIGB 300
• AS 101
• VP-102
• SB206
• PP 210
• LFX 453

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/62pk84

View source version on businesswire.com: https://www.businesswire.com/news/home/20201009005291/en/